

Synthesis, Crystal Structure and Anti-leukemic Activity of 1,3-Dihydro-1-{1-[4-(4-phenylpyrrolo[1,2-*a*]quinoxalin-3-yl)benzyl]piperidin-4-yl}-2*H*-benzimidazol-2-one

Jean Guillon ^{1,*}, Solène Savrimoutou ¹, Sandra Albenque-Rubio ¹, Noël Pinaud ², Stéphane Moreau ¹ and Vanessa Desplat ³

¹ Univ. Bordeaux, Faculty of Pharmacy, INSERM U1212, UMR CNRS 5320, ARNA, F-33000 Bordeaux, France; solene.savrimoutou@u-bordeaux.fr (S.S.); sandra.rubio@u-bordeaux.fr (S.A.-R.); stephane.moreau@u-bordeaux.fr (S.M.)

² Univ. Bordeaux, ISM—CNRS UMR 5255, F-33405 Talence CEDEX, France; noel.pinaud@u-bordeaux.fr

³ Univ. Bordeaux, Faculty of Pharmacy, INSERM U1312 - BRIC, 146 rue Léo Saignat, F-33076 Bordeaux CEDEX, France; vanessa.desplat@u-bordeaux.fr

* Correspondence: jean.guillon@u-bordeaux.fr; Tel.: +33-557-571-652

Contents

Figure S1: ¹H-NMR spectrum of compound 9

Figure S2: JMOD-NMR spectrum of compound 9

Figure S3: TOF-MS data for compound 9

Figure S4: FT-IR spectrum of compound 9




Figure S2. JMOD-NMR spectrum of compound 9.

1: TOF MS ES+
8.35e6





Figure S3. TOF-MS data for compound **9**.




Figure S4. FT-IR spectrum of compound **9**.